Q-omics provides the consensus-scored IGLCOR22-2 profile across patient tissues and cancer cell-line models. IGLCOR22-2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, IGLCOR22-2 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, IGLCOR22-2 RNA expression shows 6,157 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, LUAD, and STAD as cancer lineages where IGLCOR22-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLCOR22-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLCOR22-2 survival associations across molecular data types. IGLCOR22-2 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLCOR22-2 RNA expression–survival associations across cancer types. High IGLCOR22-2 expression shows unfavorable associations in ACC, READ, UCEC and THYM, but favorable associations in ESCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for IGLCOR22-2 RNA expression.
This table summarizes IGLCOR22-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGLCOR22-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLCOR22-2 shows higher tumor expression in LUAD. The LUAD box plot shows higher IGLCOR22-2 RNA expression in tumor versus normal tissue (log2 FC = +0.112, t-test p = .005).
This table shows molecular features associated with IGLCOR22-2 in patient tissues and cancer cell lines. In patient samples, IGLCOR22-2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
